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Inducing cancer indolence by targeting
mitochondrial Complex I is potentiated by blocking
macrophage-mediated adaptive responses
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Converting carcinomas in benign oncocytomas has been suggested as a potential anti-cancer
strategy. One of the oncocytoma hallmarks is the lack of respiratory complex I (CI). Here
we use genetic ablation of this enzyme to induce indolence in two cancer types, and
show this is reversed by allowing the stabilization of Hypoxia Inducible Factor-1 alpha
(HIF-1α). We further show that on the long run CI-deficient tumors re-adapt to their inability
to respond to hypoxia, concordantly with the persistence of human oncocytomas. We
demonstrate that CI-deficient tumors survive and carry out angiogenesis, despite their
inability to stabilize HIF-1α. Such adaptive response is mediated by tumor associated mac-
rophages, whose blockage improves the effect of CI ablation. Additionally, the simultaneous
pharmacological inhibition of CI function through metformin and macrophage infiltration
through PLX-3397 impairs tumor growth in vivo in a synergistic manner, setting the basis
for an efficient combinatorial adjuvant therapy in clinical trials.
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Developing therapeutic strategies to target cancermetabolism is currently gaining momentum and oneof the rising star metabolic approaches displaying anti-
neoplastic potential involves inhibition of respiratory complex
I (CI)1–3, the first and rate-limiting enzyme of oxidative
phosphorylation (OXPHOS). A profound revisiting of the
seminal Warburg’s hypothesis that tumors rely on aerobic
glycolysis to fuel growth has led to establish a fundamental
role for mitochondrial respiration in cancer progression. It
is now accepted that highly aggressive, malignant cancer cells
combine glycolytic and mitochondrial metabolic routes to
meet energetic and biosynthetic demands4. Indeed, to main-
tain mitochondrial respiration, aggressive human cancers
usually counterselect pathogenic mitochondrial DNA
(mtDNA) CI mutations5–8. Conversely, severe mtDNA CI
mutations are found in indolent, low-proliferative oncocytic
tumors8,9, i.e., neoplasms characterized by cells accumulating
mostly dysfunctional, aberrant mitochondria and displaying
scarce vasculature associated with destabilization of Hypoxia
Inducible Factor-1 alpha (HIF-1α), the main promoter of
vasculogenesis, glycolysis, and survival in hypoxic environ-
ment10. Oncocytomas represent an excellent case study in
oncology, as they appear to be de facto short-circuited tumors
that have become confined to a low-proliferative state due to
metabolic constraints, likely deriving from the occurrence
of high loads of pathogenic mtDNA mutations8,11 or from an
impairment in autophagy12. Converting carcinomas into
oncocytomas as an anti-cancer strategy has been proposed by
targeting autophagy master regulator ATG713. Starting from
the identification of genetic hallmarks of oncocytomas, i.e.,
severe mtDNA mutations in CI, targeting this enzyme may
be an even more efficient alternative approach to induce
indolence, as this would simultaneously cause OXPHOS
defects and the inability to adapt to hypoxia, shutting off
several essential pathways in cancer cells. However, even if
the severe CI damage could be expected to cause a metabolic
catastrophe and impede malignant progression, oncocytic
tumors linger in their indolent and slow-growing state, dis-
playing quiescent but potentially perilous features of
chemoresistance14,15. This is evident in human neoplasms
rather than in mouse models, where reversion of the benign
phenotype is technically difficult to assess for such slow-
growing cancers. It is therefore yet unclear how human CI-
deficient tumors may promote angiogenesis despite HIF1
impairment. Thus, since modes of re-adaptation to CI dys-
function seem to exist, the identification of key factors keeping
cancer cells alive is mandatory to design efficient combina-
torial strategies to eradicate tumors. At the same time, to
provide full justification for the use of CI inhibitors such as
metformin in clinical practice, the dissection of the mechan-
isms linking CI inhibition to cancer growth arrest is war-
ranted, especially those behind HIF-1α destabilization.
To fill the aforementioned gaps, we generated cancer cell
lines lacking CI, via knockout of nuclear-encoded CI core
subunit NDUFS3. Disengaging from the technical difficulties of
dealing with mtDNA genetics, these models allow fine-tuning
of NDUFS3 levels and subsequent CI activity.
We provide the proof of concept that CI ablation reduces
tumorigenic potential and allows conversion into low-
proliferative oncocytoma. Furthermore, while proving that the
loss of HIF-1α is accountable for the decreased tumorigenic
potential upon targeting CI, we additionally discover an atypical
microenvironment response mediated by protumorigenic mac-
rophages, which support survival of CI-deficient masses, and
which we synergistically targeted to significantly increase ther-
apeutic efficacy of metformin.
Results
NDUFS3 knockout induces a low-proliferative cancer pheno-
type. The molecular mechanisms linking CI impairment and
reduction of tumorigenic potential have only been partially
addressed, mainly due to difficult-to-handle cell models bearing
mtDNA mutations. Thus, with the aim to demonstrate the anti-
tumorigenic effect of CI deficiency and investigate the underlying
mechanisms, we first generated easier-to-handle cancer cell
models bearing a mtDNA-independent CI dysfunction. The
nuclear-encoded NDUFS3 gene was knocked-out to induce CI
deficiency in mesenchymal (osteosarcoma 143B) and epithelial
(colorectal cancer HCT116) cancer cells, hereafter referred to as
143B−/− and HCT−/− (Supplementary Fig. 1), with the aim to
generalize our findings in two cancer models of different tissue
origin. Genetic ablation of NDUFS3 induced a severe decrease of
CI NADH dehydrogenase activity (Supplementary Fig. 1d),
reduced CI-driven ATP production (Supplementary Fig. 2a) and
blocked mitochondrial respiration (Supplementary Fig. 2b),
resulting in a major OXPHOS defect. On the other hand,
NDUFS3 knockout induced an increase in glucose consumption
(Supplementary Fig. 2c) and lactate production (Supplementary
Fig. 2d), indicating that upregulation of glycolysis compensates
the CI defect in vitro. Concordantly, the total amount of ATP
was found to be comparable in CI-competent and deficient cells
(Supplementary Fig. 2e). Moreover, the α-ketoglutarate (α-KG)/
citrate ratio, as well as the m+ 5 citrate enrichment after labeling
with 13C-labeled glutamine, were markedly increased in CI-
deficient cells, irrespective of the cellular background (Supple-
mentary Fig. 2f–g). These data indicate that CI ablation triggers
the preferential use of reductive carboxylation to supply the
citrate pool, in agreement with previous studies in cancer cells
with severe mtDNA mutations or treated with metformin16–18.
Under selective pressures in vivo, the lack of NDUFS3 caused a
significant decrease of xenograft growth in both cancer types
(Fig. 1a) and reduced cell invasion (Fig. 1b), indicating that the
metabolic reprogramming occurring following CI disruption
(Supplementary Fig. 3a) allows cell survival but is not sufficient
to fully recover the tumorigenic and invasive potential. 143B−/−
and HCT−/− tumors displayed lower KI-67 proliferation index
(Fig. 1c) and no signs of necrosis, a known marker of aggres-
siveness, which was instead abundant in CI-competent tumors
(Fig. 1d). The cytostatic effect of CI ablation was confirmed by
a decreased caspase activation in the KO tumors, in agreement
with what we previously reported19 (Supplementary Fig. 3b).
Interestingly, CI-deficient masses were composed of eosinophilic
cancer cells (Fig. 1d) harboring swollen mitochondria with
deranged cristae (Fig. 1e, Supplementary Fig. 3c), well recapitu-
lating oncocytic lesions, which was further strengthened by the
finding that 143B−/− xenografts displayed an increased expres-
sion of PPARGC1A, the master regulator of mitochondrial
biogenesis (Supplementary Fig. 3d). Re-expression of NDUFS3
in 143B−/− cells rescued CI activity (Supplementary Fig. 3e),
mitochondrial ultrastructure and tumorigenic potential (Fig. 1f).
Taken together, these data indicate that NDUFS3 knockout
tumors recapitulated the bioenergetic features of lesions harbor-
ing mtDNA disruptive mutations, such as oncocytes, and provide
the proof of principle for the anti-tumorigenic effect of
CI damage.
Targeting CI converts malignant cancers in oncocytomas. After
establishing that tumorigenic potential of CI-deficient tumors is
reduced compared to their CI-competent counterpart, we sought
to prove that depleting CI in a well-formed, progressing mass
may represent an effective strategy to decrease or arrest growth
in vivo. NDUFS3 was constitutively expressed in 143B−/− cells
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(143B−/−NDUFS3), under the control of a transactivator negatively
regulated by doxycycline (Dox) (Supplementary Fig. 4a). By
using Dox doses which did not affect CI assembly, a complete
loss of the enzyme was observed after 9 days of treatment
(Supplementary Fig. 4b). Moreover, at doses which do not
impact tumor growth or mtDNA-encoded protein levels
(Supplementary Fig. 4c–e), Dox-mediated induction of CI loss
caused growth arrest in 85.7% of 143B−/−NDUFS3 proliferating
tumors, decreased KI-67 proliferative index and resulted in sig-
nificantly prolonged survival of the animals (Fig. 2a, b, Supple-
mentary Fig. 5). CI-depleted tumors showed clear-cut negative
NDUFS3 staining (Fig. 2c), demonstrating complete loss of the
protein and suggesting that no promotor leakage occurred.
Staining for NDUFS4 subunit, a marker of CI assembly9, was
reduced in Dox-treated 143B−/−NDUFS3 xenografts, indicating
that the enzyme was successfully targeted (Fig. 2c). Furthermore,
Dox-treated masses displayed ultrastructural mitochondrial
alterations (Fig. 2d) and lack of necrosis at tumor leading margins
(Fig. 2e), a phenotype resembling NDUFS3 knockout xenografts.
All these data demonstrate that targeting CI during cancer
progression converts malignant tumors into low-proliferative,
oncocytoma-like tumors.
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Next, we corroborated our findings in a Drosophila melano-
gaster model of tumorigenesis, in which CI abolishment was
feasible through the targeting of another crucial CI subunit,
namely the ortholog of human NDUFV1. This allowed us to
investigate whether the phenotype observed by targeting NDUFS3
might be extrapolated to any severe CI damage which would
hamper specific NADH dehydrogenase activity, leading to
NADH accumulation, as we previously showed19–21. A polarity-
deficient strain was used, in which mutations of the evolutionarily
conserved lethal giant larvae (lgl) tumor suppressor gene induce
malignant growth of the epithelial larval organs which progres-
sively grow into frank cancers, causing late individuals to die as
pre-pupae with their anterior half completely filled by giant
tumors22. In this transformed context, we induced GFP+lgl−/−
ndufv1 knockdown clones (hereafter referred to as V1KD) at
6 days after egg laying (AEL), a time when neoplastic growth
is obvious. As a control, GFP+lgl−/−lucKD clones were induced
in the same experimental conditions. The epithelial tumors were
isolated from GFP+ larvae at 8 days AEL. The CI-deficient V1KD
masses were smaller than controls (Fig. 2f, Supplementary Fig. 6a)
and cell density analysis revealed an average of 50.75% GFP+
cells in the V1KD samples versus 74.87% in the control
counterparts (Fig. 2f). Subsequently, to investigate the phenotypic
consequences of CI disruption in cells undergoing neoplastic
transformation in an otherwise wild-type organ, mimicking
mammalian cancer onset, we induced ndufv1 knockdown in a
cooperative system, extensively used to recapitulate clonal
carcinogenesis in Drosophila, where a lgl loss of function
mutation is combined with oncogenic Ras (RasV12)23. The
lgl−/−RasV12 clones in which ndufv1 was knocked-down
appeared considerably smaller than the control counterparts
and showed a lower roundness coefficient (Supplementary
Fig. 6b–c), indicating poor capacity to form three-dimensional
structures. The mitotic index measured by PH3 staining was
reduced in lgl−/−RasV12V1KD tumors (Supplementary Fig. 6d),
whereas cell death, defined by activation of caspase 3, was
comparable between the lgl−/−RasV12V1KD and control samples
(Supplementary Fig. 6e). These data confirmed that CI deficiency
reduces tumorigenic potential by decreasing the proliferation rate
of transformed cells, rather than inducing apoptosis, in line with
our previous observations19. Altogether, the data collected in the
two Drosophila cancer models sustained the findings obtained
in the mammalian systems, confirming the essential role of CI in
both initiation and progression of tumor growth, and indicating
CI as a valid target for anti-cancer therapy.
HIF-1α loss is involved in CI-null tumor growth decrease.
CI deficit in oncocytic tumors has been associated with lack of
HIF-1α stabilization10, a phenomenon also observed in xeno-
grafts carrying severe mtDNA mutations19,21 or treated with
metformin1. Indeed, HIF-1α stabilization was absent in the
143B−/− and HCT−/− tumors (Fig. 3a) and associated with a
lower expression of HIF1-responsive genes (Fig. 3b). Moreover,
143B−/−NDUFS3 xenografts, in which CI function was restored,
showed the recovery of HIF-1α activation, whereas Dox-induced
CI loss caused HIF-1α destabilization (Supplementary Fig. 7a).
Finally, staining the Drosophila HIF-1α ortholog Similar showed
lack of its nuclear accumulation in lgl−/−RasV12V1KD, which in
the control clones was evident and followed by expression of
invasion marker MMP1 (Fig. 3c), confirming HIF-1α destabili-
zation as an evolutionarily conserved mechanism associated with
CI deficiency. Interestingly, CI-deficient xenografts were pre-
valently negative for pimonidazole staining, used as the hypoxia
marker, even when left to grow until the size comparable to that
of CI-competent controls (10% of the animal weight) (Supple-
mentary Fig. 7b, c), suggesting that CI-deficient tumors barely
ever acquire a hypoxic phenotype. The rare hypoxic foci identi-
fied in 143B−/− xenografts were negative for HIF-1α staining
(Fig. 3d), allowing to hypothesize that CI deficiency causes HIF-
1α destabilization even in true hypoxia. To establish whether CI
deficiency induces defects in HIF-1α stabilization, we analyzed
HIF-1α status under controlled hypoxic environment in vitro.
143B−/− and HCT−/− cells grown under 1% O2 conditions dis-
played a delayed HIF-1α stabilization (Fig. 3e) and lower
expression of HIF1-responsive genes (Supplementary Fig. 7d),
compared to their CI-competent counterparts, demonstrating
an intrinsic defect in the HIF-1α stabilization pathway in CI-
deficient tumors. With the aim to prove that the growth deficit of
cells lacking functional CI was due to their inability to activate
HIF1, a non-degradable and constitutively expressed form of
HIF-1α24, here named triple mutant (TM), was introduced into
143B−/− and HCT−/− cells. When compared to the empty vector
controls (143B−/−Mock and HCT−/−Mock), cells constitutively
expressing the TM-HIF-1α (143B−/−TM and HCT-/-TM) dis-
played HIF-1α stabilization, translocation into the nucleus and
higher transcription of HIF1 downstream targets regardless of
normoxia (Fig. 3f, Supplementary Fig. 8a, b), and formed larger
colonies in 3D collagen/matrigel media (Supplementary Fig. 8c).
Moreover, while TM-HIF-1α did not influence the tumorigenic
potential of 143B+/+ cells (Supplementary Fig. 8d), CI-deficient
cells expressing TM-HIF-1α formed larger xenografts when
injected in nude mice (Fig. 3g, Supplementary Fig. 8e). Thus, the
growth deficit of cells lacking functional CI was at least partially
due to their inability to activate HIF1.
CI deficiency boosts PHD activity and destabilizes HIF-1α. We
proceeded to explore the molecular mechanisms linking CI
impairment with HIF-1α destabilization. The best-characterized
mode of HIF-1α regulation is the PHDs-mediated hydroxylation,
which in normoxia triggers its proteasomal degradation25. In
addition, several PHD-independent mechanisms of HIF-1α reg-
ulation have been identified26, such as reactive oxygen species
Fig. 1 NDUFS3 knockout triggers oncocytic phenotype and reduces tumorigenic potential. a Growth curves of 143B xenografts in CD-1 nude mice [n= 15,
df= 28, t(day 38)= 5.4] and HCT xenografts in ICRF nude mice [n= 8, df= 14, t(day 31)= 3.6]. Data are mean ± s.e.m. Representative tumors are shown.
Scale bars: 2 cm. b Cell invasion assay in 3D collagen-I/Matrigel media of 143B and HCT xenograft-derived cells. Representative colonies are displayed
and their margin delineated with dashed line. Scale bars: 400 µm. Quantification of invading areas of the colonies is shown [n= 3, df= 4, t(143B)= 5.578,
t(HCT)= 5.547]. Data are mean ± s.e.m. c Quantification of cells displaying KI-67 positive nuclei in 143B (n= 15, df= 28, t= 2.7) and HCT (n= 3, df= 4,
t= 3.7) tumors. Representative image of KI-67 immunohistochemistry staining is shown. Scale bars: 25 µm. Data are mean+ s.e.m. d Hematoxylin/eosin
(HE) staining and immunohistochemistry for NDUFS3 and NDUFS4 CI subunits. Representative images are shown. Scale bars: 50 µm. e Evaluation of short
mitochondrial axis width and cristae number in 143B xenografts (axis: n= 3, df= 4, t= 8.3; cristae: n= 3, df= 4, t= 5.9) and HCT cells (axis: data were
log-transformed, n= 3, df= 4, t= 2.8; cristae: n= 3, df= 4, t= 5.7). Representative electron micrographs are shown. Scale bars: 2 µm. Data are mean+ s.
e.m. f Growth curves of 143B xenografts derived from cells carrying the empty vector (143B−/−Mock) or re-expressing wild-type NDUFS3 (143B−/−NDUFS3)
in CD-1 nude mice. Data are mean ± s.e.m. [n= 6, df= 10, t(day 34)= 5.2]. Representative electron micrographs of the xenografts are shown. Scale
bars: 2 µm. In each panel, statistical significance is specified with asterisks (*p < 0.05, **p < 0.01, ***p < 0.001)
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Fig. 2 Targeting CI arrests tumor progression and converts carcinomas into oncocytomas. a Kaplan–Meier survival curves of CD-1 nude mice injected with
143B−/−NDUFS3 cells and treated with (n= 7) or without (n= 5) Dox (1 mgmL−1 in drinking water). Survival end-point: xenografts reaching 10% of animal
weight. Representative xenografts are shown. b Quantification of cells displaying KI-67 positive nuclei in 143B−/−NDUFS3 tumors treated with (n= 7) or
without (n= 5) Dox (1 mgmL−1 in drinking water) (df= 13, t= 5.539). Representative image of KI-67 immunohistochemistry staining is shown. Scale bars:
50 µm. Data are mean+ s.e.m. c Immunohistochemistry staining of CI subunits in xenografts treated with or without Dox (1 mgmL−1 in drinking water).
Representative images are shown. Scale bars: 50 µm. d Short mitochondrial axis width (n= 3, df= 4, t= 2.4) and cristae number (n= 3, df= 4, t= 3.1)
evaluation, with representative electron micrographs of xenografts treated with or without Dox (1 mgmL−1 in drinking water). Scale bars: 2 µm. Data are
mean+ s.e.m. e Hematoxylin/eosin staining of 143B−/−NDUFS3 tumors treated with Dox. Tumor margin is indicated by the dashed line. Representative
images are shown. Scale bars: 100 µm. f Immunofluorescence for caspase 3 (Cas3) of CI-competent (lgl−/−) and deficient (lgl−/−V1KD) epithelial tumors
(GFP+) of the fly. Dashed lines delineate tumor margin. Scale bars: 80 µm. Tumor size (n= 25, df= 48, t= 13.2) and the average number of GFP+
cells (n= 6, df= 10, t= 13.8) were evaluated. Data are mean+ s.e.m. In each panel, statistical significance is specified with asterisks (*p < 0.05, **p < 0.01,
***p < 0.001)
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Fig. 3 CI deficiency promotes HIF-1α destabilization. a HIF-1α and NDUFS3 western blot analysis in 143B and HCT xenografts. Vinculin was used as loading
control. b Gene expression of HIF-1α targets evaluated by qRT-PCR in 143B [n= 8, df= 14, t(LDHA)= 6.5, t(SLC2A1)= 4.5, t(VEGF)= 4.7] and HCT
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t-test assuming unequal variance was applied. Data are mean+ s.e.m. c Immunofluorescence for HIF-1α and MMP1 in Drosophila wing discs. Tumor
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and NDUFS3 western blot of 143B and HCT cells cultured in 1% O2 at indicated times. Vinculin was used as loading control. f Immunofluorescent staining
of nuclei (DAPI) and HIF-1α in 143B−/− cells carrying empty vector (Mock) or TM-HIF-1α (TM). Representative images are shown. Scale bars: 100 µm.
g Growth curves in CD-1 nude mice of 143B [n= 15, df= 28, t(day 37)= 2.2] and HCT [data were log-transformed, n= 7, df= 12, t(day 46)= 3.5]
xenografts derived from CI-deficient cells carrying empty vector (Mock) or TM-HIF-1α (TM). Data are mean ± s.e.m. Representative tumors are shown.
Scale bars: 2 cm. In each panel, statistical significance is specified with asterisks (*p < 0.05, **p < 0.01, ***p < 0.001)
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(ROS)-mediated activation of PI3K/Akt or ERK pathways which
promote HIF1Α transcription and translation27. No significant
differences in H2O2 production and, concordantly, in the total
glutathione level, between CI-competent and deficient cells were
observed (Supplementary Fig. 9a, b), and the latter displayed no
decrease but rather an increase in HIF1Α mRNA levels compared
to their control counterparts (Fig. 4a), indicating that HIF-1α
destabilization in CI-deficient cells does not involve mechanisms
affecting HIF1Α transcription. Furthermore, HIF-1α recovery was
observed after treatment with the proteasome inhibitor MG132
(Fig. 4b), indicating that the lack of CI does not affect HIF-1α
translation. In particular, MG132 caused higher accumulation
of hydroxylated HIF-1α (HIF-1α-OH) in 143B−/− and HCT−/−
cells (Fig. 4b, c), indicating an enhanced PHD activity in CI-
deficient models. Recovery of HIF-1α protein was also observed
in 143B−/− and HCT−/− cells after treatment with dimethylox-
allyl glycine (DMOG), a selective PHDs inhibitor28 (Fig. 4b),
confirming CI deficiency determines a deregulation in the PHD-
mediated degradation of the protein. Of note, PHD1/2 protein
levels were comparable between CI-competent and deficient cells
(Supplementary Fig. 9c). In agreement with our previous data
showing NADH-mediated α-KG accumulation in tumors carry-
ing CI-disruptive mtDNA mutations19,21, CI-deficient cells dis-
played a significant increase in α-KG levels compared to controls,
as well as in malate/aspartate ratio (Fig. 4d), the latter being an
indication of NADH accumulation. α-KG is known to boost PHD
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activity by increasing its affinity for oxygen29,30. Furthermore,
it has been shown that severe mitochondrial damage may cause a
sufficient reduction in oxygen consumption to increase cytosolic
oxygen concentrations regardless of the external hypoxia31. Thus,
we evaluated the intracellular oxygen status of CI-deficient cells
with the hypoxia marker pimonidazole and observed that, when
grown in controlled in vitro hypoxic conditions, 143B−/− and
HCT−/− cells experienced less intrinsic hypoxia than their CI-
competent counterparts (Fig. 4e), in accordance with the mainly
normoxic condition observed in CI-deficient xenografts (Fig. 4f
and Supplementary Fig. 7c). Taken together, these data imply that
the delay and reduction of HIF-1α stabilization in CI-deficient
cancer cells was caused by simultaneous increase in α-KG con-
centrations and reduced oxygen consumption, which together
lead to a boost of PHD activity regardless of external hypoxia.
CI-deficient tumors display stroma-associated angiogenesis.
Despite the lack of HIF-1α and lower tumorigenic potential, CI-
deficient masses, like oncocytomas, continued to progress (Sup-
plementary Fig. 7b), meaning they probably engage alternative,
HIF-1α-independent mechanisms to ensure nutrient supply. In
the context of proposing CI targeting as an anti-cancer strategy,
such growth persistence might present a potential risk of malig-
nancy. Thus, we next investigated the consequences of HIF-1α
destabilization on angiogenesis in CI-deficient tumors, with the
aim to identify the pro-survival adaptive mechanisms activated
during their development. By staining with endothelial markers
endomucin and CD31, we compared the vessels morphology in
CI-competent and deficient masses. CI-competent tumors pre-
sented with vessels characterized by a large lumen and positivity
for the pericyte marker smooth muscle actin (SMA), indicating
mature and well-perfused vasculature (Fig. 5a). Moreover, these
vessels were located in areas surrounded by hypoxia and HIF-1α-
positive cancer cells (Supplementary Fig. 10a), suggesting that
they were most likely generated via HIF1-mediated signals. On
the other hand, CI-deficient tumor vasculature in both 143B−/−
and HCT−/− xenografts was characterized mainly by small,
lumen-free and SMA-negative vessels (Fig. 5a), indicating an
impairment in vascular maturation. The re-expression of
NDUFS3 in 143B−/− cells restored HIF-1α-associated vasculature
(Supplementary Fig. 10b), whereas tumors in which CI was
depleted by Dox treatment displayed a greater number of SMA-
negative vessels than their untreated controls (Supplementary
Fig. 10c), demonstrating that immature vasculature was a con-
sequence of CI dysfunction. Moreover, complementing 143B−/−
and HCT−/− cells with TM-HIF-1α also rescued vessel matura-
tion (Supplementary Fig. 10d), indicating that lack of an efficient
vasculogenesis contributed to the lower tumorigenic potential of
CI-deficient tumors. Since SMA is also a marker of cancer asso-
ciated fibroblasts (CAFs), its staining showed that mature lumen-
bearing vessels in 143B−/− and HCT−/− xenografts were located
almost exclusively in the murine stromal component of the tumor
(Fig. 5a), an observation corroborated by staining collagen fibers
(Fig. 5b). Furthermore, as we previously demonstrated, xenografts
derived from cell lines carrying high loads (> 85%) of CI dis-
ruptive m.3571insC/MT-ND1 mtDNA mutation19 also showed
more pericyte-negative endothelial structures than their CI-
competent controls and displayed lumen-bearing vessels mainly
in the stromal component (Supplementary Fig. 10e). Overall,
histology revealed that the stromal component is more prominent
in CI-deficient than in CI-competent tumors, where it was located
mainly on the tumor periphery (Fig. 5c). We next quantified the
contribution of non-cancer cells in CI-deficient tumors at day 10
and day 30 post injection, to reconstruct the timeline of their
recruitment. At day 30, corroborating the histology results, both
143B and HCT xenografts displayed higher stromal contribution
in association with CI deficiency (Fig. 5d). These data, collected
from both epithelial and mesenchymal tumors, and from differ-
ent models of CI dysfunction, identified a more general rear-
rangement of tumor microenvironment in CI-deficient tumors,
possibly involved in supporting their proliferation. In particular,
since the stromal component of CI-deficient tumors was asso-
ciated with their vasculature, we hypothesize that the micro-
environment may be involved in compensatory mechanisms
triggered to overcome the inability of CI-deficient tumors to
activate HIF-1α-mediated angiogenesis.
Macrophage infiltration is a hallmark of CI-deficient tumors.
The role of microenvironment in supporting tumor growth is well
acknowledged, in particular as a source of pro-angiogenic fac-
tors32. However, the microenvironment component in tumors
may be highly heterogeneous and exert both protumorigenic and
anti-tumorigenic functions. Thus, to identify the components
which might support CI-deficient tumor growth, we next char-
acterized the contribution of immune cells (CD45+) and fibro-
blasts (CD31−CD45−) (Supplementary Fig. 11a). At day 10, no
difference was observed in 143B xenografts, whereas HCT−/−
tumors showed an increased contribution of each of the popula-
tions analyzed (Supplementary Fig. 11b). At day 30, both 143B
and HCT CI-deficient xenografts harbored more CD45+ cells
than their CI-competent counterparts (Supplementary Fig. 11b),
identifying immune cells abundance as a phenomenon shared
in the CI-deficient tumor microenvironment. Thus, we further
characterized the populations of the innate immune system in
our models, namely macrophages (F4/80+ Lys6G−), neutrophils
(Lys6G+ F4/80−), natural killer cells (NK, CD49b+), and den-
dritic cells (CD11c+ F4/80−) (Supplementary Fig. 11c). Of note,
a higher number of necrosis-associated neutrophils was observed
in CI-competent tumors (Fig. 6a and Supplementary Fig. 11d).
The most striking and consistent difference we observed involved
a higher number of macrophages in both 143B and HCT CI-
deficient xenografts (Fig. 6a), particularly evident from the
increase in the macrophage-to-cancer cells ratio (Fig. 6b). With
the aim to investigate whether the higher macrophage
abundance may be due to increased monocyte differentiation, we
analyzed CD11b and Ly6C markers at day 30 (Supplementary
Fig. 12a). Both tumor types harbored comparable numbers
of classical CD11b+ Ly6C+ monocytes, whereas the number
of differentiated CD11b+ LyC− monocytes was higher in CI-
deficient masses (Supplementary Fig. 12b). Indeed, the number of
CD11b+ Ly6C−F4/80+ cells was also higher in CI-deficient
tumors (Fig. 6c), suggesting that CI deficiency in cancer may
promote differentiation of CD11b+ Ly6C+ cells into macro-
phages (CD11b+ Ly6C−F480+). Strikingly, histology both at
day 10 and at day 30 (Fig. 6c), revealed a difference in
macrophage localization. While in CI-competent tumors they
were restricted mainly at the tumor periphery, in CI-deficient
tumors macrophages were found infiltrating the cancer mass
(Fig. 6d). In line with this observation, we identified the down-
regulation of macrophage migration inhibitory factor (MIF) in CI-
deficient cancer cells (Supplementary Fig. 13a). Interestingly, MIF
is a HIF1-induced protumorigenic cytokine whose down-
regulation has recently been associated with macrophage-
mediated angiogenesis33. Indeed, we corroborated reduced levels
of MIF in 143B−/− tumors and established that the com-
plementation with TM-HIF-1α rescues MIF expression and
reduces the number of macrophages in 143B−/− tumors
(Supplementary Fig. 13b–d), suggesting the increased presence of
macrophages in CI-deficient tumors may be a consequence of
HIF1 inactivation.
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Since changes in the CAFs distribution were observed on
histology (Fig. 5c and Fig. 6e), and since both CAFs and tumor
associated macrophages (TAMs) have been shown to exert well-
characterized pro-angiogenic roles32,34, it is reasonable to hypothe-
size they might converge in promoting survival in CI-deficient
tumors. However, in line with the flow cytometry data at day 30, the
number of single CAFs in the tumor was comparable between the
two groups (Supplementary Fig. 14a), indicating that CI-competent
and deficient cells were equally able to activate fibroblasts, which
was also confirmed in vitro (Supplementary Fig. 14b). On the other
hand, the number of single macrophages was higher in CI-deficient
tumors than in control masses (Fig. 6d), suggesting that
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macrophages might contribute more than CAFs in progression of
CI-deficient tumors. The prominent contribution of macrophages
in association with CI-deficient cancer cells was furthermore
observed in tumors in which the CI defect was due to high mutant
loads of the m.3571insC/MT-ND1 mutation (Supplementary
Fig. 15a), as well as in Drosophila lgl−/−RasV12V1KD tumors where
the macrophage component (NimC1+) of the hemocytes (the fly
blood cells) was found increased compared to their controls
(Supplementary Fig. 15b). Additionally, the treatment of CI-
competent xenografts with metformin, besides reducing tumor
growth at comparable levels with genetic CI KO (Supplementary
Fig. 15c), led to a higher number of intra-tumor macrophages than
their untreated controls, as well as to a higher number of CD11b+
F4/80+ Ly6C− cells (Supplementary Fig. 15d, e). Thus, our data
imply that targeting CI results in an increase of macrophages within
the tumor, possibly in order to support survival.
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Inhibiting TAMs increases efficacy of CI targeting. TAMs may
exert either pro-inflammatory or pro-angiogenic functions during
tumor progression, depending on whether they are polarized
toward M1 or M2 population, respectively35. Since abnormal
vascularization, comparable to the Endo+ SMA− structures
identified in CI-deficient cancers (Fig. 5a) has been associated
with M2-mediated pro-angiogenic signals36, we analyzed CI-
competent and deficient xenografts for the markers generally
associated with M1 (iNOS) or M2 (CD206, Arg1) macrophage
populations. In all samples analyzed, the number of CD206-
expressing macrophages increased from day 10 to day 30, when
more than 70% of TAMs were CD206+, whereas the number of
macrophages expressing iNOS was generally low in all samples
analyzed (10–20% in HCT and 1–4% in 143B), suggesting that
the activation of protumorigenic TAMs is a property of both CI-
deficient and control tumors (Supplementary Fig. 16a). Interest-
ingly, iNOS expression, usually associated to M1 macrophages,
was observed in CD206high and Arg1high population (Fig. 7a).
There was no increase in the relative expression of any of the
markers in CI-deficient tumors (Supplementary Fig. 16b),
excluding the possibility that CI-deficient cancer cells are more
capable to polarize TAMs to M2. Nonetheless, the total number
of CD206+ and Arg1 expressing macrophages was higher in
143B−/− and HCT−/− masses, whereas the number of iNOS
expressing TAMs was either comparable or higher in CI-
competent tumors (Fig. 7b), showing that protumorigenic mac-
rophages were generally more abundant in CI-deficient tumors.
These data demonstrate that targeting CI did not potentiate M2
polarization, but was instead associated with higher macrophage
abundance, in agreement with the increase in monocyte differ-
entiation and higher macrophage infiltration identified in CI-
deficient tumors (Fig. 6b–d).
Collectively, our data suggest that CI-deficient xenografts could
rely on TAMs to promote survival. To prove this hypothesis, we
depleted macrophages during CI-deficient tumor development.
HCT−/− xenografts were treated with liposomes containing
clodronate, a bisphosphonate that induces selective apoptosis of
phagocyting macrophages. Compared to vehicle-treated controls,
mice receiving clodronate showed almost complete absence of
xenograft growth (Fig. 7c). Despite the anti-tumorigenic effect of
clodronate was observed also in HCT+/+ tumors (Supplementary
Fig. 17a), the treatment did not prevent HCT+/+ cells from
forming frank tumors, with histology similar to the untreated
controls (Supplementary Fig. 17b). Instead, HCT−/− xenografts
treated with clodronate formed masses not larger than 10 mm3,
which upon excision revealed to be white, indicating complete
absence of vascularization (Fig. 7c). Similarly, when 143B−/− cells
were injected in more permissive Rag1−/−FVB/n mice,
clodronate-treated tumors presented with a lower number of
SMAn-egative vessels (Supplementary Fig. 17c, d). Importantly,
histology of clodronate-treated HCT−/− masses revealed exten-
sive necrosis, normally absent from CI-deficient xenografts
(Fig. 7c), demonstrating that CI-deficient cells depend on
macrophages to form tumors. This finding has the potential
clinical implication of enhancing metformin treatment in cancer,
if combined with drugs blocking macrophages activity. Thus, we
treated HCT+/+ xenografts simultaneously with both metformin
and colony stimulating factor 1 (CSF1) receptor inhibitor PLX-
3397, with the aim to specifically block CSF1-dependent
macrophage infiltration in tumors. In line with the data from
CI-deficient models, the combination of drugs significantly
increased the efficacy of both PLX-3397 and metformin alone
(Fig. 7d), proving that targeting macrophages is a promising
approach to potentiate the effects of CI inhibitors in cancer, in a
combinatorial regimen.
Discussion
Targeting CI is considered to be a promising anti-cancer ther-
apeutic strategy, according to the bulk of data collected both in
experimental settings1,37,38 and in clinical trials using
metformin2,39. This is indirectly supported by the negative
selection of severe CI defects in human tumors, which in the rare
occasions when they do occur, associate with the development of
low-proliferative oncocytomas8. We here exploit a fine-tunable
system of CI ablation in different cancer types to trigger con-
version to oncocytomas, and demonstrate that HIF-1α destabili-
zation is accountable for such indolent behavior. Nonetheless, the
conflicting data regarding metformin efficacy40–43 and the fact
that CI-deficient lesions continue to strive, point out the trig-
gering of adaptive responses which our models allowed to dissect.
In particular, we identified TAM-associated survival response in
CI-deficient tumors and demonstrated that macrophage inhibi-
tion further decreased their tumorigenic potential.
Although HIF-1α destabilization has been previously described
in CI-deficient cancer models, human oncocytomas, as well as in
xenografts treated with metformin1,10,19, the molecular mechan-
isms linking these phenomena are still unclear. In particular, at
least two players undergo significant changes in cancer cells
deprived of CI, converging toward the promotion of PHD activity
and HIF-1α destabilization regardless of hypoxia, one of them
being the accumulation of α-KG30. Further, our results support
the concept that OXPHOS alterations cause the redistribution
of intracellular O2 from respiratory enzymes to PHDs31. In this
metabolic frame of HIF-1α regulation, α-KG and O2 likely
decrease the ability of CI-deficient cells to sense hypoxia, which is
reflected in the hypoxic foci lacking nuclear HIF1 in CI-deficient
tumors.
Fig. 6 Macrophage infiltration is a hallmark of CI-deficient tumor microenvironment. a Flow cytometry analysis of innate immune system populations
in 143B (n= 4, df= 6) and HCT (n= 5, df= 8) tumors. The contribution of macrophages (F4/80+) [t(143B)= 2.8, t(HCT)= 2.8], neutrophils (Lys6G+)
[t(143B, data were log-transformed)= 5], dendritic cells (CD11c+ F4/80−) and natural killer cells (CD49b+) is shown at day 30 post injection in ICRF
nude mice. Data are mean+ s.e.m. b Macrophage to cancer cell ratio in 143B (n= 4, df= 6, t= 3.21) and HCT (n= 5, df= 8, t= 4.834) xenografts. Data
are mean+ s.e.m. Representative dot-plots display contribution of macrophages (F4/80+, in blue) and neutrophils (Ly6G+, in red) among 100,000
acquired events (SSC-A/FSC-A plots) and their relative amount among CD45+ population (F4/80/Ly6G plots). All other cell populations are represented
in gray. The gates indicate population percentages. c Flow cytometry analysis of undifferentiated (CD11b+ Ly6C+) and differentiated (CD11b+ Ly6C−)
monocytes in 143B (n= 4, df= 6, t= 4.213) and HCT (n= 3, df= 4, t= 2.674) xenografts at day 30 post injection in ICRF nude mice. Representative
contour-plots are shown. The gates indicate population percentages. Data are mean+ s.e.m. d The number of macrophages (F4/80+) infiltrating tumor
tissue counted per field of view (FOV) in xenografts at day 10 [143B (n= 3, df= 4, t= 8), HCT (n= 3, df= 4, t= 9)] and at day 30 [143B (n= 4, df= 6,
t= 5.376), HCT (n= 3, df= 3, t= 3.201)] post injection. Representative images of immunohistochemistry analysis for macrophage marker F4/80 in
xenografts are shown. Dashed lines delineate the tumor margin. Scale bars: 50 µm. Data are mean+ s.e.m. e Representative image of immunofluorescent
staining of the SMA+microenvironment component in HCT xenografts. Dashed lines delineate the tumor margin. The arrows indicate the collective
CAF formations. Scale bars: 50 µm. In each panel, statistical significance is specified with asterisks (*p < 0.05, **p < 0.01, ***p < 0.001)
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Due to the great number of pro-survival mechanisms activated
by HIF1, it is reasonable to imply that the loss of HIF-1α
challenges progression of CI-deficient masses. By complementing
CI-deficient cells with TM-HIF-1α, we have provided proof for
such concept. The consequences of HIF-1α destabilization in CI-
deficient tumors are at least dual. As previously shown, it pre-
vents the acquisition of a typical Warburg profile20, which is
linked to the upregulation of several pro-glycolytic genes HIF1
is responsible to transcribe. More importantly, as demonstrated
here, HIF1 inactivation impairs tumor vasculature in CI-null
tumors, compromising their nutrient supply.
However, despite the loss of HIF-1α and maintenance of a low-
proliferative phenotype, CI-deficient tumor growth persists. In
this respect, our observation of a different histological archi-
tecture in CI-deficient masses revealed that the striking abun-
dance of microenvironment component in these tumors may be
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accountable for their alternative, HIF-1α-independent nutrient
supply. Even though this needs to be corroborated in a fully
immunocompetent system, it is well-known that cells from the
tumor microenvironment promote its progression44, and that the
ultimate vascular phenotype of a neoplasm results from conver-
ging/synergistic cancer cell-autonomous and microenvironment-
mediated pro-angiogenic signals32. Hence, abnormalized vessels
typical of myeloid-driven vasculogenesis45, the infiltration of
macrophages observed in CI-deficient tumors and the reduction
of their number when HIF-1α activity was complemented by TM-
HIF-1α, all together imply that macrophage abundance is a
consequence of HIF-1α destabilization in CI-deficient tumors.
This is furthermore supported by the fact that CI-deficient
tumors display MIF downregulation, a phenomenon recently
associated with macrophage-mediated vascularization activated as
a compensatory response upon anti-VEGF treatment33. Indeed,
since MIF is a known HIF1-responsive gene and CI targeting
ultimately leads to lack of HIF1, our data indicate that TAM
abundance may be a consequence of MIF downregulation.
Intriguingly, MIF is a classical pro-survival cytokine, meaning
that its downregulation may also contribute to the lower
tumorigenic potential of the CI-deficient cancer cells. However,
at the same time its downregulation paradoxically releases a
microenvironment-mediated compensatory response, classifying
MIF in the ever-growing group of double-edged oncojanus cancer
genes46. Considering the complexity of the cross-talk between
cancer cells and microenvironment, we acknowledge that
mechanisms apart from the HIF–MIF axis likely contribute to
macrophage abundance in CI-deficient tumors. The role of CAFs
needs to be further explored, since their secretion of extracellular
matrix proteins supports macrophage migration, and CAFs also
secrete their own pro-angiogenic factors32. It is interesting to
note that repair-like patrolling macrophages (CD11b+ Ly6C
−F4/80+), we here identify as associated with CI-deficient can-
cers, have been described to promote angiogenesis and fibrosis in
the wound47, meaning that their abundance in the context of
cancer might explain the fibroblast contribution we observe in
CI-deficient tumors.
Blocking TAM infiltration further reduced the tumorigenic
potential of CI-deficient xenografts, as well as metformin-treated
tumors, indicating that simultaneous targeting of CI and mac-
rophages is an efficient synergistic approach to reduce tumor
growth. Of note, CI inhibitors such as metformin and
macrophage-targeting agents both exhibit cytostatic effects on
cancer cells. Confining cancers in a low-proliferative state ought
to be considered a valid alternative approach to cancer eradica-
tion, since turning cancer into a chronic disease slows down its
genetic evolution and allows the pool of progressing cancer cells
to competitively consume available resources48. Interestingly,
both metformin and macrophage inhibitors are economical
drugs, currently used in the clinics, with limited side effects when
administered in diabetic and osteoporotic patients, respectively.
Overall, our results corroborate targeting CI as a valid anti-cancer
strategy, although this may be overcome, at least in certain types
of cancers, by macrophage-mediated adaptive response. We
hence look forward to the clinical trials exploring the combina-
torial effects of drugs that hit two such essential players of the
adaptive process of cancer cells.
Methods
Cell lines and treatments. Osteosarcoma 143B Tk− cells and colorectal cancer
HCT116 cells were used, both carrying wild-type mtDNA. 143B cells were
purchased from ATCC (#CRL-8303) and HCT116 cells were a kind gift from
Prof. Paolo Pinton from the University of Ferrara. Cell origin was authenticated
using AMPFISTRIdentifiler kit (Applied Biosystems #4322288) and their STR
profile corresponded to their putative background (Supplementary Fig. 1a). For
basal conditions, cells were cultivated in Dulbecco’s modified Eagle medium
(DMEM) high glucose (Euroclone #ECM0749L), supplemented with 10% FBS
(Euroclone #ECS0180L), L-glutamine (2 mM, Euroclone #ECB3000D), penicillin/
streptomycin (1 ×, Euroclone #ECB3001D), and uridine (50 µg mL−1,
Sigma-Aldrich #U3003), in an incubator with a humidified atmosphere at 5% CO2
and 37 °C. Cells were replaced by a fresh batch after 15 passages and mycoplasma
testing was performed before disposal and after each thawing (approximately every
2 months). Experiments in hypoxia were performed using an Invivo2 300 (Baker
Ruskinn) chamber, set at 5% CO2, 37 °C and 1% O2. Where indicated, cells were
incubated for 3 h with dimethyloxalylglycine [DMOG (1 mM), Sigma-Aldrich
#D3695] or MG132 (10 μM, Sigma-Aldrich #M7449) and 1 h with pimonidazole
(100 μM, Hypoxiprobe #70132-50-3).
Genome editing for generation of NDUFS3 knockout. Plasmids containing
cDNA of NDUFS3-targeted zinc finger endonucleases were purchased from Sigma-
Aldrich (#CKOZFND15168) and were used according to the manufacturer’s
instructions. Briefly, the plasmids were purified and transcribed in vitro using
MessageMax caping kit (Cell Script #C-MMA60710), Poly adenylation kit
(Epicentre #PAP5104H), and purified using MegaClear kit (Life Technologies
#AM1908). The pool of zinc finger endonucleases mRNAs (2.5 µg each) was
transfected using Transit-mRNA transfection kit (Mirus #2225) into 70% confluent
cells. Cells were split 48 h after transfection and DNA was extracted using Mam-
malian Genomic DNA Miniprep Kit (Sigma-Aldrich #G1N350). Non-homologous
repair efficiency was evaluated by Fluorescent PCR using KAPA2G Taq polymerase
(Kapa Biosystems #KK5601) with 58 °C annealing and primers forward [Flc]
CTGCCACAAGGAGCTAGGAC and reverse GCACAGGGAGATAAAAGGCA.
Clonal selection was performed in order to identify the cells with frameshift
NDFUS3 mutations. Selection media used for the single-cell growth in 96-well
plates was composed of DMEM high glucose (Euroclone #ECM0749L), supple-
mented with 20% FBS (Euroclone #ECS0180L), L-glutamine (2 mM, Euroclone
#ECB3000D), penicillin/streptomycin (1 ×, Euroclone #ECB3001D), uridine (50 µg
mL−1, Sigma-Aldrich #U3003), L-Tryptophan (32 mg/L, Sigma-Aldrich #T0254),
and Nicotinamide (8 mg L−1, Sigma-Aldrich #72340). DNA extraction from 96-
well plates was performed using 8 µL of Lysis Solution (Sigma-Aldrich #L3289) and
80 µL of Neutralization Buffer (Sigma-Aldrich #N9784) per sample. Upon geno-
typing, heterozygous clones were first expanded, and subjected to a subsequent
second transfection with NDUFS3 zinc finger pool. This step led to the selection of
homozygous frameshift NDUFS3 mutants and homozygous wild-type revertants
(Supplementary Fig. 1b). The latter were used as isogenic controls in all experi-
ments described here. NDUFS3 genotype was confirmed by Sanger sequencing
using KAPA2G Taq polymerase (Kapa Biosystems #KK5601) and Big Dye protocol
(Life Technologies #4337451). After the validation of single NDUFS3−/− clones,
they were pooled for the experiments that followed (143B n= 5, HCT n= 3).
Generation of cells with inducible NDUFS3 knockout. To create a stable
transgenic cell line that re-expresses NDUFS3 and allows its inducible knockout,
the Retro-X Tet-Off Advanced Inducible Expression system (Clontech #632105)
Fig. 7 TAMs support CI-deficient tumors growth and their inhibition enhances metformin effects. a Representative dot plots displaying macrophage
populations expressing CD206, Arg1, and iNOS in HCT+/+ and HCT−/− xenografts, and in fluorescence minus one (FMO) controls. iNOS (light blue)
was set as the first front and Arg1 (dark blue) as the second front population, compared to CD206 (dark purple) and remaining immune cells (green).
b Flow cytometry analysis of macrophage subpopulations markers CD206, Arg1, and iNOS in 143B and HCT tumors at day 30 post injection in ICRF
nude mice. Statistics for 143B: n= 4, df= 6, t(CD206)= 3.756, t(Arg1)= 3.219, t(iNOS)= 3.143. Statistics for HCT: n= 3, df= 4, t(CD206)= 14.96,
t(Arg1)= 3.348. Data are mean+ s.e.m. c Tumor growth curves of HCT−/− xenografts in ICRF nude mice treated with or without clodronate [n= 8,
df= 14, t(day 47)= 3.524]. Representative tumors are shown. Scale bars: 1 cm. Data are mean ± s.e.m. d Hematoxylin/eosin (HE) staining of HCT−/−
xenografts in ICRF nude mice treated with or without clodronate. Scale bars: 50 µm. e Tumor growth curves and volume at day 27 post-treatment of
HCT−/− xenografts in CD-1 nude mice, treated with metformin (2 mgmL−1 in drinking water) or PLX-3397 (1.5 mg per day by oral gavage) alone and in
combination [data were log-transformed, n= 5–7, df(metformin versus double treatment)= 10, t(metformin versus double treatment)= 2.539]. Data
are mean ± s.e.m. In each panel, statistical significance is specified with asterisks (*p < 0.05, **p < 0.01, ***p= 0.001)
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was used by following manufacturer’s instructions. First, 3 × 106 amphotrophic
Phoenix (phxA) cells (ATCC® No. CRL-3213™) were transiently transfected with
20 μg of pRetroX-Tet-Off Advanced vector and 0.9 μg of helper plasmid using
Lipofectamine 2000 (Thermo Fisher #11668027). PhxA cells were maintained in
the presence of transfection mix for 16 h, then switched to DMEM for 24 h, after
which the retroviral supernatant was collected, filtered (0.45 μm), supplemented
with 8 μg mL−1 hexadimethrine bromide, and 2 mL was used to stably transfect
143B cells (50 × 103) in 6-well plates. The later were then (i) centrifuged 1800 r.p.m.
at 32 °C for 45 min and incubated at 32 °C for 2 h, (ii) replenished with fresh
retroviral supernatants, re-centrifuged as indicated and incubated at 32 °C for
additional 4 h, (iii) replenished with normal medium and incubated overnight,
(iv) replenished with 4 mL of fresh retroviral supernatant, centrifuged as indicated
and incubated at 32 °C for 5 h, (v) replenished with normal medium and incubated
48 h, (vi) replenished with normal medium containing G418 (400 μg mL−1, Sigma
#A1720) and incubated for 48 h. The surviving cells were maintained in medium
supplemented with 100 μg mL−1 G418. Single-cell cloning of selected cells was then
performed and luciferase was transfected in each clone in order to identify cells
with optimal transactivator activity. In particular, 2 μg of pRetroX-Tight-Pur-Luc
Control Vector was transiently transfected using X-tremeGENE HP DNA Trans-
fection Reagent kit (Roche #06366236001) in 143B cells (80 × 103) seeded in 6-well
plates in the standard medium but containing Clontech tetracycline-free FBS. Each
clone was then treated with/without Dox (100 ng mL−1, Sigma #D9891) and after
48 h, cells were harvested and processed according to the Dual-Luciferase Reported
Assay System (Promega #E1910) protocol. The luciferase activity was generally
high in absence of Dox and low in cells cultivated with Dox medium. Five clones
with lowest+Dox luciferase activity were pooled together and then the second
viral transduction was performed as described above, using pRetroX-Tight-Pur-
NDUFS3 vector. The selection of cells that uptaken the plasmid was performed
using puromycin (0.5 μg mL−1, Sigma #P8833). Single-cell cloning was performed
to identify clones showing lack of NDUFS3 after Dox treatment and five clones
were pooled to obtain 143B−/−NDUFS3 cell line.
Generation of cells carrying TM-HIF-1α. Wild-type sequence of HIF1A cDNA
was cloned in pGEM (Promega #A1360) vector and mutagenesis was performed
using Quickchange Site-Directed Mutagenesis kit (Agilent #200518), following
manufacturer’s instructions, to induce the mutations at the PHD hydroxylation
sites following previously described indications24. In particular, three mutations
were inserted in the HIF1Α sequence, to substitute the prolyl hydroxylase (PHD)-
targeted prolines and Factor Inhibiting HIF (FIH)-targeted asparagine with resi-
dues that cannot be hydroxylated (P402A, P564G, and N803A). The triple mutant
HIF1A was then transferred to pMSCV-Puro retroviral vector (Clontech #PT3303-
5). The empty vector and the vector containing TM-HIF-1α were then used to
transduce 143B and HCT116 cells by following phxA transduction protocol
described above. Cells carrying the vectors were selected with 2 μg mL−1 pur-
omycin (Sigma #P8833) and maintained in medium supplemented with 1 μg mL−1
puromycin. Clonal selection was performed to identify the clones with the highest
TM-HIF-1α protein levels in normoxia and a pool of 20 clones was made.
SDS-PAGE and western blot. Whole lysates of cultured cells and freshly snap-
frozen xenograft samples were prepared in RIPA buffer (Tris–HCl pH 7.4 (50
mM), NaCl (150 mM), SDS (1%), Triton (1%), EDTA pH 7.6 (1 mM)) supple-
mented with protease inhibitors (Roche #11873580001), and quantified by Lowry
protein assay (Bio-Rad #5000116). Samples were separated by SDS-PAGE and
transferred onto nitrocellulose membrane using Turbo-pack system (Bio-Rad
#1704159SP5). Membranes were blocked 30 min at 37 °C and incubated with
primary antibodies using following dilutions/conditions: anti-NDUFS3 (AbCam
#177471) 1:1000/1-h at room temperature (RT); anti-HIF1α (GeneTex
#GTX127309) 1:2000/1-h at RT; anti-Vinculin (Sigma-Aldrich #V9131) 1:10,000/
1-h at RT; anti-pimonidazole (Hydroxyprobe #4.3.11.3) 1:3000/2-h at 37 °C; anti-
HIF-1α-OH (Cell Signaling #3434) 1:500/O/N at 4 °C; anti-VDAC (AbCam
#154856) 1000/2-h at RT; anti-MT-CO2 (AbCam #110258) 1:1000/2-h at RT; anti-
MIF (AbCam #175189) 1:5000/1-h at RT; anti-ACTB (Santa Cruz #SC-1615)
1:500/1-h at RT; anti-cleaved Caspase 3 (Cell Signaling Technology #9661) 1:1000/
O/N at 4 °C; anti-PHD1 (Abcam #ab108980) 1:1000/O/N at 4 °C, anti-EGLN1/
PHD2 (Novus Bio #NB100-137) 1:1000/O/N at 4 °C; anti-GAPDH (Sigma-Aldrich
#G8795) 1:20,000/2-h at RT. Washes were performed 4 × 5min using TBS-Tween
[0.1% Tween 20 (Sigma-Aldrich #P9416) in Tris Buffered Saline] and incubation
with secondary antibodies (Jackson ImmunoResearch Laboratories #111035144
and #111035146), diluted 1:20,000 in TBS-Tween, was performed for 30 min at RT.
Developing was performed by using Clarity Western ECL Substrate (Bio-Rad
#1705061) and exposing with ChemiDoc XRS+ (Bio-Rad). For anti-HIF-1α-OH
antibody, Western Breeze system (Life Technologies #WB7106) was used for
secondary antibody and developing solutions, following the manufacturer’s
instructions. Raw acquisition images are presented in Supplementary Fig. 18.
Mitochondrial-enriched fraction preparation. Mitochondria-enriched fractions
were obtained by subcellular fractionation (5–10 × 106 cells) in presence of digi-
tonin (50 μg mL−1). Crude mitochondria were obtained from 15–20 × 106 cells.
The cell pellet was suspended in ice-cold buffer containing 200 mM mannitol,
70 mM sucrose, 1 mM EGTA, 10 mM HEPES (pH 7.6) and mechanically disrupted
with a glass/teflon Potter-Elvehjem homogenizer. Differential centrifugations
(600 × g for 10 min at 4 °C followed by 14,000 × g for 10 min at 4 °C) were per-
formed to separate crude mitochondria from other subcellular fractions. Samples
were stored at −80 °C.
High-resolution clear native PAGE (hrCNE). For complex I in-gel activity
(CI-IGA) assay and western blotting analysis, mitochondrial-enriched fractions
were resuspended in mitochondrial buffer (750 mM aminocaproic acid, 50 mM
Bis-Tris, pH= 7) and solubilized by adding DDM/protein ratio of 2.5 (g/g).
Suspension was incubated on ice for 10 min and then centrifuged at 13,000 × g for
15 min. Aliquots of supernatants (80 µg protein) were separated by 4–16% first
dimension hrCNE gradient gel (NativePAGE™ 4–16% Bis-Tris Protein Gels, Invi-
trogen, #BN1002BOX) using as anode buffer 25 mM pH= 7 and as cathode buffer
50 mM Tris, 7.5 mM Imidazole, 0.02% n-Dodecyl β-D-maltoside (Sigma-Aldrich
#D4641), 0.05% sodium deoxycholate (Sigma-Aldrich, #D6750). Proteins were
either transferred onto a nitrocellulose membrane at 100 V for 1 h at room
temperature or complex I in-gel activity (CI-IGA) assay was performed. Briefly, gel
was rinsed in cathode buffer and incubated at room temperature for 15 min in a
solution containing 2 mM Tris pH= 7.4, 0.5% 3-(4,5-Dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT, Sigma-Aldrich, #M5655), 0.02% reduced
β-Nicotinamide adenine dinucleotide (NADH, Sigma-Aldrich, #N8129) under
constant agitation and protected from light.
Measurement of ATP synthesis rate. The rate of mitochondrial ATP synthesis
driven by CI, CII, and CIII was measured in digitonin-permeabilized cells. After
trypsinization, cells (10 × 106 mL−1) were suspended in a buffer containing
150 mM KCl, 25 mM Tris–HCl, 2 mM EDTA (ethylenediaminetetraacetic acid),
0.1% bovine serum albumin, 10 mM potassium phosphate, 0.1 mM MgCl2, pH 7.4,
kept at room temperature for 15 min, then incubated with 50 μg mL−1 digitonin
until 90–100% of cells were positive to Trypan Blue staining. Aliquots of 3 × 105
permeabilized cells were incubated in the same buffer in the presence of the
adenylate kinase inhibitor P1,P5-di(adenosine-5′) pentaphosphate (0.1 mM) and
OXPHOS complexes substrates, chemiluminescence was determined as a function
of time with Sirius L Tube luminometer (Titertek-Berthold, Pforzheim, Germany).
The chemiluminescence signal was calibrated with an internal ATP standard after
the addition of 10 μM oligomycin. The rates of the ATP synthesis were normalized
to protein content and citrate synthase (CS) activity49.
Glucose consumption. Glucose consumption was determined by using the
glucose oxidase (GO) assay kit (Sigma-Aldrich #GAGO20) scaling down the
manufacturer protocol to a final volume of 1 mL. Briefly, cells were seeded in 6-well
plates (1 × 105 cells/well) in high glucose medium. After 48 h, cells were washed
in PBS and incubated with DMEM-high glucose without phenol red. Aliquots of
100 µL of medium were taken at time 0 and after 24 h and 48 h of incubation and
3 µL of samples were used to determine the glucose concentration, by the enzy-
matic reaction of glucose oxidase coupled to peroxidase-mediated oxidation of
reduced o-Dianisidine (λ= 540 nm, 30 min, 37 °C). The data obtained were nor-
malized on cell number.
Lactate production. Cells were seeded in 6-well plates (3 × 105 cells/well) in 2 mL
of high-glucose medium. After 24 h and 48 h, aliquots of medium were collected
and de-proteinated with 6% perchloric acid, vortexed and incubated in ice for
1 min. Samples were centrifuged at 13,000 r.p.m. at 4 °C for 2 min and the lactate
concentration in supernatants was determined by measuring NADH (λ= 340 nm;
ε= 6.22 mM−1 cm−1) production in a buffer containing 320 mM glycine, 320 mM
hydrazine, 2.4 mM NAD+ and 2 UmL−1 L-lactic dehydrogenase (Sigma-Aldrich
#L1006) after 30 min of reaction at 37 °C. Data were expressed as pmoles of lactate
produced per cell.
Oxygen consumption rate. Mitochondrial respiration was evaluated using the
Seahorse XFe Cell Mito Stress Test Kit (Seahorse Bioscience #103015-100)
following the manufacturer instructions. Cells were seeded (3 × 104 cells/well) into
XFe24 cell culture plate and allowed to attach for 24 h. Cell culture media was
replaced with XF media (Seahorse Bioscience #103334-100). OCR was measured
over a 3 min period, followed by 3 min of mixing and re-oxygenation of the media.
For Mito Stress Test, complete growth medium was replaced with 670 μL of
unbuffered XF media supplemented with 10 mM glucose pH 7.4 pre-warmed at
37 °C. Cells were incubated at 37 °C for 30 min to allow temperature and pH
equilibration. After an OCR baseline measurement, 70 μL of oligomycin, carbonyl
cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), and rotenone plus anti-
mycin A were sequentially added to each well to reach final concentrations of 1 μM
oligomycin, 0.25 μM FCCP, and 1 μM rotenone and antimycin A. Three mea-
surements of OCR were obtained following injection of each drug and drug
concentrations optimized on cell lines prior to experiments. At the end of each
experiment, the medium was removed and SRB assay was performed to determine
the amount of total cell proteins as described above. OCR data were normalized to
total protein levels (SRB protein assay) in each well. Each cell line was represented
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in five wells per experiment (n= 3 replicate experiments). Data are normalized
on SRB absorbance and expressed as pmoles of O2 per minute.
ATP content measurement. Total ATP content was determined by using the
ATPlite Luminescence Assay System (Perkin Elmer #6016943). Cells (3–1.5 × 104)
were seeded in a 96-wells plate in high glucose DMEM. After 24 h, cells were
washed twice with PBS and incubated with high glucose DMEM or with galactose
DMEM. ATP content was measured after 16 h following the manufacturer pro-
tocol. Luminescence was detected using a multilabel counter Victor3 (Perkin
Elmer). Data are normalized on cell number detected by SRB assay.
Evaluation of Krebs-cycle metabolite concentrations. Absolute metabolite
concentrations were measured with Carcinoscope analysis [Human Metabolome
Technologies (HMT)] that uses capillary electrophoresis coupled to time of flight/
triple quadrupole mass spectrometry. Metabolites were extracted using 100%
methanol supplemented with 550 μL of internal standard solution provided by
HMT from 2 to 5 million cells seeded on 90 mm plate. The metabolite con-
centrations of in vitro cell preparations were normalized to the number of viable
cells. Tumor samples were grinded in liquid nitrogen before proceeding with the
analysis. The measurement was corroborated by LC-based metabolite quantifica-
tion at the Metabolomics Core Technology Platform of the Excellence cluster
CellNetworks (University of Heidelberg; grant no. ZUK 49/2010-3002962).
Citrate 13C isotopomer analysis. For mass isotopomer analysis, cells were incu-
bated for 3 h either with DMEM high glucose (Euroclone #ECM0749L) supple-
mented with [13C] labeled glutamine (2 mM) or with DMEM (Life Technologies
#11966-025) supplemented with sodium pyruvate (110 mg L−1, Sigma-Aldrich
#P2256) and [13C] labeled glucose (25 mM). Nutrients labeled with 13C were
purchased from Cambridge Isotope Laboratories (#CLM-1396 and #CLM-1822).
Metabolite extraction was performed as described above and the isotopomer dis-
tribution was evaluated with F-Scope analysis (Human Metabolite Technologies).
Reactive oxygen species measurement. To determine the H2O2 production, cells
were incubated with 2 μM 2,7-dichlorodihydrofluorescein diacetate (H2DCFDA)
(Life Technologies #D399) added to 100,000 cells, for 30 min at 37 °C. The cells
were then collected and the reaction was stopped by placing them in an ice bath
for 5 min. The cells were disrupted by treatment with Triton X-100 (2%) and
centrifuged at 2500 × g for 20 min at 4 °C. The supernatant was used to measure
fluorescence emission (excitation, 485 nm; emission, 535 nm) using a multilabel
counter Victor3 (Perkin Elmer, Turku, Finland). The amount of H2O2 produced
was calculated by using a standard curve of 2,7-DCFH2 in which 1 μM of 2,7-
DCFH2 represented 1 μM of H2O250.
3D colony growth assay. Tumor cells were seeded in 24-well dishes at 500 cells/
dish in 150 µL of 2:1 Rat tail collagen-I (Corning #354249) and Matrigel (Corning
#356234), yielding a final collagen concentration of 4 mgmL−1 and a final Matrigel
concentration of 2 mgmL−1. The wells were pre-coated with 50 µL of collagen/
matrigel media. The colonies were maintained in DMEM in basal conditions and
analyzed after 14 days. For data in Fig. 1b the invasive margins of the colonies were
counted in 10 random colonies per sample (n= 3). For data in Supplementary
Fig. 8c, colony number and average diameter were evaluated in 10 random colonies
per sample (n= 6).
Xenograft growth. For in vivo studies, nu/nu mice (CD-1® Nude Mouse Crl:CD1-
Foxn1n) were purchased from Charles River Laboratories. Where indicated, ICRF
nude or Rag1−/−FVB/n mice available at The Francis Crick Institute Biological
Research Facility were used. We have complied with all relevant ethical regulations
for animal testing and research. The animals were treated according to institutional
guidelines and regulations at Paracelsus Medical University Salzburg, The Francis
Crick Institute and University of Bologna. Respectively, the study received ethical
approval from the Salzburg State Ethics Research Committee (20901TVG/112), UK
Home Office (project license PPL number P83B37B3C) and Italian Ministry of
Health (authorization code 437/2018-PR). Five to six-week-old female mice were
subcutaneously injected with a 100 μL suspension of 5 × 106 cells in serum free
medium and matrigel (Corning #356234) in the right flank of the animal. For
experiments in Figs. 3g, 7c and Supplementary Fig. 17a–d, a bilateral inoculation
was performed. Xenograft size was measured with a sliding caliper twice a week,
according to the formula: volume=width × height × length/2. Mice were sacrificed
either simultaneously, when the first xenograft reached 10% of animal weight
(Fig. 1a, f, Fig. 3g, Fig. 7c, Supplementary Fig. 8d, Supplementary Fig. 15c and
Supplementary Fig. 17a–d), or consecutively, when each animal reached xenograft
volume corresponding to 10% of animal weight or met the termination criteria
(Fig. 2a and Fig. 7e). For the Dox-induced experiment, 3% sucrose with or without
Dox (1 mgmL−1) was added into the drinking water of the mice, which were
sequentially randomized in Dox-treated and control group when tumor would
reach 450 mm3. For CSF1-R inhibition, PLX-3397 (Pexidartinib, Apex Bio-
Technology #B5854) was dissolved in DMSO and suspension was made by dilution
in the aqueous solution of 0.5% hydroxypropyl methyl cellulose (HPMC, Sigma
#H7509) and 1% polysorbate (PS80, Sigma #59924). The drug (1.5 mg per mouse)
was administered by oral gavage for 20 consecutive days with 100 µL of suspension.
Metformin was added to drinking water at concentration of 2 mgmL−1. Fresh
water/metformin pouches were provided twice weekly. The PLX-3397 and/or
metformin treatment was started when a tumor would reach 50 mm3. Prior to the
sacrifice (3 h before) all animals were injected intraperitoneally with pimonidazole
(60 mg kg−1, Hypoxyprobe #70132-50-3) diluted in saline solution. For the clo-
dronate treatment experiments in Fig. 7c and Supplementary Fig. 17a–d, the ani-
mals were pre-injected intraperitoneally with PBS or clodronate liposomes (100 µL,
ClodronateLiposomes, Liposoma BV) on the day prior to cell injection. On the day
of tumor cell injection, 5 × 106 cells in growth factor reduced matrigel (100 µL)
were injected subcutaneously, immediately followed by injection of 40 µL of PBS or
clodronate liposomes at the same position. The mice continued to receive intra-
peritoneal injection of liposomes twice weekly (100 µL).
Immunohistochemical staining. The samples were formalin fixed following
standard protocols. Tissue sections (4 µm) were deparaffinized in xylene, rehy-
drated in absolute 2-propanol followed by heat-induced epitope retrieval in TE-T
buffer (10 mM Tris pH 8.0, 1 mM EDTA, 0.05% Tween 20) for 40 min at 95 °C and
20 min at RT. Sections were equilibrated with phosphate-buffered saline containing
0.5% Tween 20 (PBS-T pH 7.4). Primary antibodies were diluted in Antibody
diluent with background reducing components (Dako #S3022) and incubated at
RT for 30 min. Blocking, secondary antibodies staining and development were
carried out using the Envision Detection System (Dako #K4007 and #K4011)
according to the manufacturer’s instructions. Slides were counterstained with
hematoxylin. The following primary antibodies were used: rabbit monoclonal anti-
NDUFS3 (1:200, Abcam #177471); rabbit polyclonal anti-HIF-1α (1:350, Sigma-
Aldrich #HPA001275); mouse monoclonal anti-pimonidazole (1:400, Hypoxyp-
robe #Mab-4.3.11.3); rabbit monoclonal anti-CD-31 (1:50; Abcam #28364); mouse
monoclonal anti-KI-67 (1:100, Dako #M7240); mouse monoclonal anti-MT-CO1
(1:1000, Abcam #14705); mouse monoclonal anti-NDUFS4 (1:1000, Abcam
#55540), and rat monoclonal F4/80 (1:100, eBiosciences #14-4801). Neutrophil
marker 2b10 antibody was developed in house at The Francis Crick Institute.
For macrophage staining with anti-F4/80, trypsin-based antigen retrieval (0.05%
trypsin in 0.1 mM Calcium chloride solution, pH 7.8) was performed for 30 min at
37 °C, and biotinylated goat anti-rat secondary antibody (Sigma-Aldrich #A9037)
was used, together with VECTASTAIN ABC-HRP Kit (Vector Laboratories #PK-
4005). Hematoxylin/eosin and Masson’s trichrome staining were performed on
4 µm sections following standard protocols. For evaluation of KI-67 positive nuclei,
cells were counted at ×20 magnification in 5–10 fields of view per tumor.
Macrophages (F4/80+) were counted at of ×20 magnification in three fields of
view per tumor.
Electron microscopy. Samples were fixed using paraformaldehyde (2%) and glu-
taraldehyde (2.5%) in cacodylate buffer (0.1 M) for 24 h and then washed, kept in
the cacodylate buffer at +4 °C, fixed with glutaraldehyde (2.5%) and 1% osmium
tetroxide, dehydrated in alcohol and propylene oxide and embedded in Epon 812.
Sections (1 μm) were stained with 1% toluidine blue for morphology control and
electron microscopy area selection. The sections were observed with JEM-1011
transmission electron microscope (JEOL Ltd). At least two different areas were
observed for each tumor. Mitochondrial morphology was evaluated by measuring
short mitochondrial axis and counting cristae in 50 mitochondria per sample.
Quantitative real-time PCR. Gene expression was analyzed following minimal
information for publication of Quantitative Real-Time PCR (qRT-PCR) Experi-
ments guidelines51. In particular, RNA was extracted using Trizol (Life Technol-
ogies #15596018) for cell lines, and Mammalian Genomic DNA Miniprep Kit
(Sigma-Aldrich #RTN70) for snap-frozen xenograft samples. High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems #4368814) was used for preparation
of cDNA with random hexamers starting from 300 ng of RNA. Primer sequences
were designed using Primer3 software52. The presence of 3′ intra/inter primer
homology was ruled out using IDT OligoAnalyzer tool (http://eu.idtdna.com/
analyzer/Applications/OligoAnalyzer/) and the availability of the target sequence
was evaluated by prediction of the cDNA secondary structure using Mfold web
server53. Primer sequences are reported in Supplementary Table 1. The PCR
reaction was performed with GoTaq qPCR Master Mix (Promega #A6002) and run
in 7500 Fast Real-Time PCR System (Applied Biosystems), using following con-
ditions: 95 °C 5min; 45 cycles of 95 °C 15 s and 60 °C 45 s. The calculations were
performed following 2−ΔΔCT method [CT(control)−CT(experiment)], where the
control was calculated as the average CT value deriving from control samples. The
normalization was performed using TBP. The statistical significance was calculated
using the ΔCT values [CT(gene of interest)−CT(reference gene)] for each biolo-
gical replicate in a group and applying Student's t-test54. Primer sequences are
available in Supplementary Table 1.
Fly lines and treatments. Fly lines: yw, hs-Flp; l(2)gl4/CyO; UAS-lucKD—yw,
hs-Flp; l(2)gl4/CyO; UAS-NDUFV1KD—w; l(2)gl4/CyO; act:CD2:Gal4, UAS-GFP/
TM6b—w; l(2)gl4, FRT40A/In(2LR)GlaBc; UAS-RasV12, UAS-lucKD/TM6b—w;
l(2)gl4, FRT40A/In(2LR)GlaBc; UAS-RasV12, UAS-NDUFV1KD/TM6b—yw,
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hs-flp, tub-Gal4, UAS-GFP; tub-Gal80, FRT40A. For experiments in Fig. 2f, larvae
of the right genotypes were selected at 144 ± 2 h development, transferred in a
1.5 mL vial plugged with foam and immersed for 2 min in a water bath at 37 °C.
After the heat-shock, larvae were immediately transferred onto fresh food and
allowed to grow for additional 48 h before dissection. For experiments in Sup-
plementary Fig. 5c and Supplementary Fig. 9e, larvae were heat-shocked at 48 ± 4 h
development for 10 min in a water bath at 37 °C and allowed to grow for additional
72 h before dissection. All the experiments were carried out at 25 °C. In all the
control experiments, the UAS-lucKD line was used as an irrelevant dsRNA. For
validation of the VIKD construct, UAS-VIKD flies were crossed with act-Gal4 flies;
the progeny was collected at the end of the larval life and processed as to obtain
the total RNA for a qRT-PCR analysis.
Drosophila disc isolation and volume calculation. For experiments in Fig. 2f,
192 ± 2 h larvae displaying GFP+ cells were selected under a Nikon SMZ1000
fluorescence stereoscope. Collected larvae were dissected in cold PBS, tumorous
imaginal wing discs were isolated and photographed. Major and minor axes were
measured for each wing disc with ImageJ (NIH) and volumes were calculated
approximating disc shape to a spheroid with depth=width. A minimum of
25 discs were analyzed for each replicate.
Immunofluorescent staining. For xenograft analysis, the samples were formalin
fixed following standard protocols. Tissue sections (4 µm) were deparaffinised
in xylene, rehydrated in absolute 2-propanol followed by citrate antigen retrieval
(10 mM sodium citrate, pH 6) for 15 min at 95 °C and 20 min at RT. Blocking was
performed with goat serum (Abcam #156046) for 10 min at RT and incubation
with Alexa Fluor secondary antibodies (488-goat anti-mouse diluted 1:500 and
555-goat anti-rat diluted 1:350) for 40 min at RT. The following primary antibodies
were used: rat anti-Endomucin (1:200, Santa Cruz #SC-65495) and mouse anti-
SMA (1:750, Dako #M0851). Slides were mounted with Vectashield Antifade
Mounting Medium with DAPI (Vector Laboratories, #H-1200). Vessel size was
evaluated by measuring the longer diameter of 30 endomucin positive cells per
tumor and avoiding areas of collective fibroblast infiltration. Fibroblasts
(SMA+Endo−) and immature vessels (Endo+SMA−) were counted in five fields of
view at ×20 magnification per tumor. Images were taken with Zeiss Axio Scope.
Z1 scanner using ZEN software (Carl Zeiss Microscopy GmbH, Germany). For
pimonidazole staining, 8 µm sections of snap-frozen samples were prepared and
FITC-conjugated mouse monoclonal anti-pimonidazole antibody (1:400, Hypox-
yprobe #Mab-4.3.11.3) was used following manufacturer’s indications. In vitro
immunofluorescence for anti-HIF-1α (1:350, Sigma-Aldrich #HPA001275) was
performed using manufacturer’s indications. Images for pimonidazole and HIF-1α
staining were taken with an inverted Nikon Eclipse Ti-U epifluorescence micro-
scope, using Metamorph software (Universal Imaging). For Drosophila experi-
ments, tissues isolated from selected larvae were fixed and stained according to
standard protocols. Primary antibodies: rabbit anti-cleaved caspase 3 (1:100, Cell
Signaling #9961), mouse anti-MMP1 (1:50, DSHB, Iowa University), rabbit anti-
Sima/HIF-1α55, mouse anti-NimrodC1 (original antibody by Istvan Andó sent
by Julia Cordero), rabbit polyclonal anti-phospho-histone H3 (Ser10) (1:100,
Cell Signaling Technology #9701). Secondary antibodies: anti-mouse 555 Alexa
Fluor (1:200) and anti-rabbit Cy5 DyLight (Jackson Laboratories, 1:500). Confocal
images were processed as a whole with Adobe Photoshop. All the images shown
represent a single confocal stack. Clone area, clone roundness and macrophage
area were calculated by using ImageJ (NIH). For clone area (Fig. 2f) and roundness
(Supplementary Fig. 5c), 20 random clones from separate discs were imaged.
For cell density and caspase 3 (Supplementary Fig. 5b) quantification, marked
cells present in four areas of 100 × 100 µm captured at different focal planes were
counted for each tumor, for a total of 6 and 10 tumors, respectively.
Flow cytometry. Cell isolation was performed as previously described56. Briefly,
xenograft samples (~50 mm3) were digested immediately after the sacrifice for 40
min at 37 °C with Liberase TL (Sigma #5401020001), Liberase TM (Sigma
#5401135001) and DNaseI (Sigma #DN25) in HBSS and passed through a 100 µm
strainer. Hypotonic lysis with Red Blood Cell Lysis Buffer (Sigma #11814389001)
was performed and remaining cells were washed with MACS buffer (2 mM EDTA,
0.5% BSA in PBS), blocked using FcR Blocking Reagent (Miltenyi #130-092-575)
and incubated with panels of pre-labeled antibodies. In parallel, spleen, lung and a
control tumor tissue were digested together and stained for fluorescence minus one
(FMO) reading which was considered while setting the gating strategy. Following
panels were used: Panel 1 (for discrimination of non-cancer versus cancer cells, and
for the analysis of the immune cell/fibroblast contribution in the tumor): anti-
CD298-APC (clone LNH-94, Biolegend #341706), anti-CD45-APC780 (clone 30-
F11, eBioscience #47-0451-80), and anti-CD31-PeCy7 (clone 390, eBioscience #25-
0311-82); Panel 2 (for analysis of the tumor macrophage, neutrophil, natural killer
cell and dendritic cell contribution): anti-anti-CD45-PE (clone 30-F11, eBioscience
#12-0451-82), anti-CD11b-ef450 (clone M1/70, eBioscience #48-0112-82), anti-F4/
80-APC780 (clone BM8, eBioscience #47-4801-80), anti-Ly6G-APC (clone 1A8,
BD Bioscience #560599), anti-CD11c-PeCy7 (clone N418, Biolegend #117317),
and anti-CD49b-FITC (clone 30-F11, Biolegend #108905). Panel 3 (for analysis
of M1/M2 protumorigenic macrophages): anti-CD45-BV421 (Biolegend #103133),
anti-F4/80-APC780 (clone BM8, eBioscience #47-4801-80), anti-CD206-APC
(clone C068C2, Biolegend #141707), anti-Arg1-PECy7 (clone A1exF5, eBioscience
#25-3697-82), and anti-iNOS-PE (CXNPT, eBioscience #12-5920-82). Panel 4
(for analysis of monocyte differentiation): anti-CD45-BV421 (Biolegend #103133),
anti-CD11b-PECy7 (clone M1/70, Biolegend #101215), anti-Ly6C-APC (Biolegend
#128016), and anti-F4/80-APC780 (clone BM8, eBioscience #47-4801-80). All
antibodies were used at 1:100 dilution, apart from the anti-CD45 which was diluted
1:300. Between 300,000 and 500,000 cells were stained. Dead cells were stained
with DAPI. For Arg1 and iNOS intracellular staining Intracellular Fixation and
Permeabilization Buffer Set (eBioscience #88-8824-00) was used by following
manufacturer’s indications, together with LIVE/DEAD Fixable Blue Dead Cell
Stain (Invitrogen #L34962). The samples were run on LSRFortessa cell analyzer
(BD Biosciences) and data was analyzed by BD FACSDIVA Software (BD
Bioscience) and Flow Jo (Tree Star Inc.) software.
Gel contraction assay. To assess fibroblast activation toward a CAF phenotype,
normal murine-derived breast fibroblasts57 were seeded in 24-well dishes at 20,000
cells/well in 100 µL of 2:1 Rat tail collagen-I (Corning #354249) and Matrigel
(Corning #356234), yielding a final collagen concentration of 4 mgmL−1 and a
final Matrigel concentration of 2 mgmL−1. Conditioned media from a 48 h culture
of 100,000 cancer cells (500 μL= 1/4 of the volume), was added and gel-
detachment from the well edge was followed.
Cytokine array. Rag1−/−FVB/n Xenograft-derived cell cultures were generated
by a 10-day cultivation of liberase-digested tissue in basal conditions. Supernatant
(0.5 mL) was taken 2 days after medium renewal and analyzed with human
Proteome Profiler Array kit (R&D Systems, ARY005B) following manufacturer’s
instructions.
Statistical analysis. GraphPad Prism version 7 (GraphPad Software Inc., San
Diego, CA, USA) was used to perform statistical tests and create bar plots and
graphs. Unless stated otherwise, a two-tailed unpaired Student’s t-tests assuming
equal variance were performed to compare averages. When the F-test to compare
variances between the two groups was significant, the data were transformed
(y′= logy) prior to the t-test calculus. In the few cases where log transformation
did not correct variances, a t-test for unequal variances was applied. For each
experiment, at least three biological replicates were analyzed. In vitro analyses
were repeated by at least two independent experiments. In vivo experiments were
repeated at least twice for data presented in Fig. 1a, Fig. 3g, Fig. 5a–c, Fig. 6b,
Fig. 6d, Supplementary Fig. 16a, and Fig. 17c. For each experiment, p-values
(*p < 0.05, **p < 0.01, ***p < 0.001), t-values (t) and degrees of freedom (df) are
indicated in figure legends, as well as the specification whether the log transfor-
mation or the t-test for unequal variances was performed. Moreover, where indi-
cated, standard error of the mean (s.e.m.) is represented by the error bars. Survival
curves were estimated using the Kaplan–Meier product-limit method and com-
pared using a log-rank test (Mantel–Cox).
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that data supporting the findings of this study are available within
the paper and its supplementary information files.
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